Persistent activation of the Abl tyrosine kinase in the BCR-ABL fusion protein is the major cause of chronic myeloid leukemia (CML). Among many other substrates BCR-ABL phosphorylates STAT5 and Src family kinases (SFK). Activated pSTAT5 is essential for initial transformation and maintenance of the disease. Cytokine-induced phosphorylation on tyrosine 694 typically leads to nuclear accumulation of pSTAT5 and target gene expression. We verified that in BCR-ABL-positive progenitor cells from a CML patient and in K562 cells pSTAT5 is cytoplasmic. However, upon ectopic expression of BCR-ABL p210 in non-myeloid cells, co-transfected STAT5A is phosphorylated on Y694 and localized in the nucleus arguing for an additional factor mediating cytoplasmic retention in CML cells. Expression of the SFK v-Src, Hck or Lyn together with STAT5A results in phosphorylation on Y694 and cytoplasmic retention. Upon coexpression of BCR-ABL and individual SFK the cytoplasmic retention of activated STAT5A mediated by v-Src and Hck but not Lyn is dominant over nuclear translocation induced by BCR-ABL. Cytoplasmic retention depends on the kinase activity of SFK and is mediated through the interaction of the SH2 domain of STAT5A with the SFK. Interestingly, nuclear accumulation of STAT5A as a result of activation by FLT3-ITD, an oncogene found in acute myeloid leukemia, cannot be prevented by coexpression of SFK. Importantly, inhibition of SFK in K562 cells restored nuclear accumulation of pSTAT5A, enhanced STAT5 target gene expression and increased colony formation. Thus, SFK mediate cytoplasmic retention of pSTAT5A in BCR-ABL-positive cells. Cytoplasmic pSTAT5A in CML cells might balance the controversial functions of STAT5 in cellular senescence and differentiation versus G 1 /S progression and survival.
INTRODUCTION
Chronic myeloid leukemia (CML) is caused by the BCR-ABL protein, a chimeric gene product resulting from a reciprocal chromosomal translocation between chromosomes 9 and 22. As a consequence of the fusion with BCR, the Abl kinase is constitutively active and phosphorylates numerous substrates on tyrosine residues. 1 In BCR-ABL-positive cells the transcription factor STAT5 is activated through phosphorylation of a critical tyrosine residue.
2 pSTAT5 is essential for the initiation and maintenance of CML in murine models of the disease. [3] [4] [5] STAT5 represents the highly homologous proteins STAT5A and STAT5B, which share 96% amino acid sequence identity. They are members of the family of signal transducers and activators of transcription (STATs). In canonical STAT signaling phosphorylation of a single-conserved tyrosine residue results in dimerization of pSTAT through reciprocal SH2 domain-phosphotyrosine interaction, nuclear accumulation and DNA-binding of pSTAT dimers, and finally induction of target genes. 6 STAT5 is essential for hematopoiesis, immunity, mammary differentiation and liver function. 7 In regular cytokine signaling STAT activation occurs downstream of cytokine receptors through receptor associated Janus tyrosine kinases. During hematopoiesis, activation by phosphorylation of Y694 and subsequent nuclear translocation of STAT5A in response to hematopoietic cytokines such as erythropoietin, thrombopoietin and granulocyte-macrophage colony-stimulating factor is of central importance. 8 Some growth factors that signal through receptor tyrosine kinases can also activate STAT5. Finally, non-receptor tyrosine kinases such as Src family kinases (SFK) and Abl phosphorylate both STAT5 isoforms and in parallel STAT3. 9 Intriguingly, pSTAT5 is found mainly in the cytoplasm of BCR-ABL-positive leukemic cells, despite the activating tyrosine phosphorylation that typically leads to nuclear accumulation. There, involvement of STAT5A in a signaling network with phosphoinositide 3-kinase (PI3K) and the adapter protein Gab2 has been shown using the constitutively active mutant STAT5A (S710F). These interactions promote cell growth through the activation of Akt. 10 However, the functional requirements for cytoplasmic localization of activated STAT5A in BCR-ABL-positive CML have not been determined yet.
CML can be successfully treated with the Abl kinase inhibitor imatinib. More recently, the therapeutic potential of second generation inhibitors that target both Abl and SFK such as dasatinib 11 and bosutinib 12 has been emphasized. Moreover, cytoplasmic or podosomal localization of pSTAT5A has been reported upon activation through the SFK Src 13 or Hck.
14 Therefore, we asked whether BCR-ABL acts like Src resulting in cytoplasmic retention of pSTAT5A. Alternatively, cytoplasmic retention of pSTAT5A in BCR-ABL-positive cells could be mediated by other factors, such as SFK.
In this study, we confirm the cytoplasmic localization of pSTAT5A in BCR-ABL-positive CD34 þ progenitor cells from a patient diagnosed in the untreated chronic phase of CML and in BCR-ABL-positive K562 cells. However, upon co-transfection of BCR-ABL and STAT5A in several non-myeloid cell lines, pSTAT5A was found to be nuclear. We identified SFK as essential mediators of cytoplasmic retention of pSTAT5A in BCR-ABL-positive cells. A direct interaction of the SH2 domain of STAT5A with SFK contributes to cytoplasmic retention of the transcription factor.
RESULTS
Predominant cytoplasmic localization of pSTAT5A in BCR-ABLpositive CML cells Cytoplasmic localization of pSTAT5A in BCR-ABL-positive leukemic cells has been reported. 10 To confirm these observations, the subcellular localization of STAT5A in isolated CD34 þ progenitor cells from a BCR-ABL-positive CML patient at diagnosis who has not been treated with kinase inhibitors was analyzed by immunofluorescence. STAT5A is predominantly located in the cytoplasm (Figure 1a, upper panel) . Staining of the cells with an antibody that recognizes the conserved phosphotyrosine motifs of pSTAT5A and pSTAT5B revealed that in the patient's CD34 þ cells, cytoplasmic STAT5 is activated (Figure 1a, lower panel) .
The subcellular localization of STAT5A was also analyzed in two human leukemic cell lines: MOLM-13, a FLT3-ITD-positive AML cell line, and K562, a BCR-ABL-positive CML cell line. Activation of STAT5 has been reported for both cell lines. 15, 16 Staining of STAT5A indicates a cytoplasmic localization in K562 cells but a nuclear localization in MOLM-13 cells (Figure 1b) . Persistent phosphorylation of STAT5 was detected in lysates of both cell lines (not shown). Thus, cytoplasmic localization of pSTAT5A The cells were permeabilized and prepared for immunofluorescence using STAT5A (upper image) or pY694/ 699-STAT5A/B (lower image) antibodies and a Cy2-labeled secondary antibody. (b) MOLM-13 and K562 cells were fixed with methanol and stained for STAT5A using a STAT5A-specific primary and Cy2-labeled secondary antibody. (c) K562 cells were transiently transfected with STAT5A-eCFP and fixed with methanol. DRAQ5 was added for nuclear staining. Cells were analyzed by confocal microscopy. DIC, differential interference contrast. Scale bars: 10 mm. seems to be rather specific for BCR-ABL-positive CML cells. Fluorescent STAT5A-eCFP is cytoplasmic in transfected K562 cells (Figure 1c ) as has been observed for endogenous STAT5A.
Ectopic expression of BCR-ABL in a non-myeloid cell line results in nuclear accumulation of STAT5A To study the molecular mechanism of cytoplasmic retention of activated STAT5A in a cellular system more suited for microscopy, HEK293 cells were stably transfected with BCR-ABL using the FlpIn T-Rex system for defined integration of the transgene and its inducible expression. Four hours after induction with doxycycline BCR-ABL could be detected using an Abl or a P-Abl antibody (Figure 2a) . BCR-ABL expression was accompanied with tyrosine phosphorylation of transiently co-transfected STAT5A-eYFP. STAT5 phosphorylation reached saturation after 8 h of induction, whereas BCR-ABL levels increased over 48 h. Interestingly, in HEK T-Rex cells, after induction of BCR-ABL for 16 h STAT5A-eYFP is nuclear, whereas in the non-induced cells, STAT5A-eYFP is equally distributed between cytoplasm and nucleus ( Figure 2b ). Nuclear translocation of STAT5A-eCFP was also observed upon transient overexpression with BCR-ABL in HEK293T cells (Figure 2c ). Similar observations were made with murine embryonic fibroblasts and HeLa cells (not shown). From these findings, we concluded that a cofactor might be needed for cytoplasmic retention of pSTAT5A in CML cells.
Activation of STAT5A by the SFK v-Src, Hck and Lyn results in cytoplasmic retention of STAT5A Cytoplasmic retention of STAT5A upon activation by constitutively active Src has been reported. 13 Therefore, SFK are promising candidates which could mediate cytoplasmic retention of pSTAT5A in BCR-ABL-positive leukemia. Indeed, when we co-transfected STAT5A-eYFP with STAT3-eCFP and v-Src-DsRed in MCF7 cells, STAT3-eCFP accumulated in the nucleus, while STAT5A-eYFP stayed in the cytoplasm (Figure 3a) . The fact that STAT3 is nuclear, but STAT5A is not, shows that v-Src-DsRed co-transfection does not interfere with the general nuclear import machinery, but specifically leads to cytoplasmic retention of STAT5A. To test whether the same is true for endogenous protein, we stained endogenous STAT5A. STAT3-deficient murine embryonic fibroblasts were used because in these cells STAT5 expression is increased and readily detectable by immunofluorescence. 7, 17 In unstimulated cells, STAT5A is equally distributed between the cytoplasmic and the nuclear compartment (Figure 3b Next, we asked whether cytoplasmic retention of activated STAT5A can also be achieved with other SFK, which are more relevant in hematopoietic cells and implicated in myeloid neoplasms. 18, 19 Therefore, we co-transfected Hck-eYFP or LyneCFP with STAT5A-eCFP or STAT5A-eYFP in HEK293T cells. Interestingly, transfection of both kinases led to cytoplasmic retention of STAT5A (Figure 3c ) despite the activating phosphorylation of Y694 (Figures 4a and b) . Src is constitutively phosphorylated in the BCR-ABL-positive leukemic cell line K562 ( Figure 5b , lane 1). In addition, these cells express the activated SFK Hck and Lyn (data not shown). The requirement of SFK kinase activity for cytoplasmic retention of STAT5A in K562 cells was investigated by the use of the Src kinase inhibitor PP1. Because the specificity of kinase inhibitors critically depends on the concentration, 21 we titrated the amount of the Src inhibitor PP1, which efficiently reduces phosphorylation of Src but does not affect BCR-ABL (not shown). Treatment of K562 cells for 1 h up to 24 h with 0.1 mM PP1 reduced tyrosine phosphorylation of Src significantly, whereas BCR-ABL phosphorylation was unaffected ( Figure 5b , lanes 2 and 3). Tyrosine phosphorylation of STAT5 was weakly reduced in the presence of PP1, probably because not only BCR-ABL but also SFK contribute to STAT5 phosphorylation.
Next, we investigated whether inhibition of SFK affects the distribution of endogenous STAT5A in BCR-ABL-positive K562 cells. Treatment of K562 cells with 0.1 mM PP1 for 1 or 2 h resulted in a redistribution of STAT5A from the cytoplasmic to the nuclear compartment, leading to yellowish colored nuclei in the merged images as a result of the colocalization of the red nuclear marker with the green staining of STAT5A ( Figure 5c , left images). This interpretation is substantiated by image analysis using the profile function of the confocal microscope ( Figure 5c , right diagrams). Incubation with 0.1 mM PP1 also prevented cytoplasmic retention of STAT5A-eYFP in HEK293T cells transfected with Hck-eCFP and BCR-ABL (Figure 5d ). From these findings, we conclude that cytoplasmic retention of activated STAT5A in BCR-ABL-positive cells is mediated by SFK. Short-time treatment of K562 cells with 0.1 mM PP1 led to increased expression of the STAT5 target genes cis and pim1 as measured by RT-PCR (Figure 5e ). Enhanced gene expression might be a result of elevated levels of activated STAT5A in the nucleus. At the same time, the decrease of cytoplasmic pSTAT5A is accompanied by a reduced phosphorylation of Akt (Figure 5f ) most probably because of interference with the STAT5A/Gab2/PI3K signaling network ( Figure 7) . 10 In this experiment, PP1 is as effective as imatinib in the reduction of Akt phosphorylation. BCR-ABL through pY177 activates ERK and Akt. ERK phosphorylation is completely blocked by imatinib but not affected by PP1, confirming the specificity of kinase inhibition. These findings argue for the involvement of SFK and STAT5 in Akt activation through BCR-ABL. Although we did (a) T-REx-293-BCR-ABL cells were transiently transfected with STAT5A-eYFP. Twenty-four hours after transfection BCR-ABL expression was induced with 8 ng/ml doxycycline (Dox) for the indicated times. Cellular lysates were analyzed by immunoblotting using antibodies against pY412-Abl, Abl, pY694/699-STAT5A/B, GFP and lamin as a loading control. (b) Subcellular localization of STAT5A-eYFP was analyzed in T-REx-293-BCR-ABL cells before and after treatment with doxycycline (8 ng/ml) for 16 h. Cells were fixed with methanol and analyzed by confocal microscopy. (c) HEK293T cells were transiently transfected with STAT5A-eCFP and BCR-ABL. After fixation with methanol cells were permeabilized and stained for BCR-ABL using a primary antibody against Abl and a secondary Cy3-conjugated antibody. Cells were analyzed by confocal microscopy. DIC, differential interference contrast. Scale bars: 10 mm. . Endogenous STAT5A was stained using a STAT5A-specific antibody and a Cy2-or an Alexa Fluor-488-labeled secondary antibody. The cells were analyzed by confocal microscopy and intensity profiles along the red arrows generated with the ZEN2009 software. cyt., cytoplasm; nucl., nucleus. (c) HEK293T cells were transiently transfected with Hck-eYFP and STAT5A-eCFP or Lyn-eCFP and STAT5A-eYFP. After 24 h cells were fixed with methanol. Cells were analyzed by confocal microscopy. Scale bars: 10 mm.
not observe effects on proliferation and cell cycle kinetics of K562 cells, we found a significant increase in clonal growth after PP1 inhibitor treatment (Figure 5g ).
STAT5A strongly interacts with Src kinase Next, we studied whether a direct interaction contributes to cytoplasmic retention of activated STAT5A by SFK. It is well established that STAT5 as well as STAT3 is strongly phosphorylated by SFK. survival and expansion. 24 Therefore, it is not surprising that hyperactivation of STAT5 in hematopoietic stem and progenitor cells results in factor independent growth and contributes to blood malignancies. Activated STAT5 is a hallmark in myeloproliferative neoplasms or lymphoid disease, where it serves as a prognostic factor for disease outcome. 8, 25 Activation typically results in nuclear accumulation of pSTAT5, subsequent DNA-binding and finally gene induction. However, in certain myeloproliferative neoplasms such as BCR-ABL-positive CML and KIT(D816V)-positive mastocytosis, 26 pSTAT5A is localized in the cytoplasm. The involvement of cytoplasmic pSTAT5A in a signaling network with Gab2, PI3K and Akt was shown to be required for prosurvival signaling. 10, 27 However, the mechanism that prevents nuclear accumulation of pSTAT5A in BCR-ABLpositive cells remained enigmatic.
We confirmed the cytoplasmic localization of pSTAT5A in CD34 þ progenitor cells from a BCR-ABL-positive CML patient and in the BCR-ABL-positive K562 cell line. In contrast, in the FLT3-ITDpositive AML cell line, MOLM-13 activated STAT5A was nuclear. We found that upon co-transfection with BCR-ABL in non-myeloid Cells were fixed with methanol and stained with a STAT5A antibody and a Cy2-labeled secondary antibody. Nuclei were stained with DRAQ5. Cells were analyzed by confocal microscopy and intensity profiles along the red arrows generated with the ZEN2009 software. cyt., cytoplasm; nucl., nucleus. (d) HEK293T cells were transiently transfected with Hck-eCFP, STAT5A-eYFP and BCR-ABL. Cells were treated with 0.1 mM PP1 Src kinase inhibitor for 1 h and then fixed with methanol. Fixed cells were permeabilized and stained for BCR-ABL using an Abl antibody and a secondary Cy3-labeled antibody. Cells were analyzed by confocal microscopy. DIC, differential interference contrast. Scale bars: 10 mm. (e) mRNA was isolated from K562 cells treated for 1 h with 0.1 mM PP1 and untreated cells. cDNA was synthesized and used for quantitative RT-PCR. The mRNA levels of cis and pim1 were quantified and normalized to the mRNA level of hprt1. The bar charts were generated from four independent experiments. Error bars represent the standard deviation of the mean. (f ) K562 cells were treated with 0.1 mM PP1 for 1 and 24 h or 0.5 mM imatinib for 1 h. Cellular lysates were prepared and protein phosphorylation was analyzed by immunoblotting using antibodies against pS473-Akt, Akt1/2, pY412-Abl, Abl, pT202/Y204-ERK1/2 and ERK1/2. (g) For colony-formation assays, K562 cells were mixed with methylcellulose medium (500 cells/ml) supplemented with the indicated concentrations of PP1 or imatinib or without any inhibitor. Seven days after initial plating colonies were counted. Colony-forming units were normalized to the untreated control samples. Error bars represent the standard deviation of the mean of four independent experiments. *Pp0.05, **Pp0.01, ***Pp0.001.
Cytoplasmic retention of activated STAT5 in CML N Chatain et al cells, pSTAT5A is nuclear similar to the FLT3-ITD-positive AML state. We hypothesized that an additional factor mediates cytoplasmic retention of pSTAT5A in BCR-ABL-positive myeloid cells. Src has been reported to phosphorylate STAT5A on the critical tyrosine residue without inducing nuclear accumulation. 13 In contrast, STAT5B in mammary epithelial cells 13 and STAT3 accumulate in the nucleus upon phosphorylation by constitutively active Src. The SFK Hck and Lyn are typically expressed in myeloid cells 29 and are activated by the p210 isoform of BCR-ABL. 18 We found that Hck and Lyn, similar to Src, phosphorylated STAT5A and at the same time prevented nuclear accumulation of the transcription factor.
Interestingly, Src and Hck prevented nuclear localization of pSTAT5A in the presence of BCR-ABL but Lyn failed to do so. However, cytoplasmic retention of pSTAT5A induced by Src and Hck was not always dominant over nuclear accumulation induced by an oncogenic kinase. STAT5A activated by FLT3-ITD is nuclear even in the presence of Hck. This finding is in agreement with our observation of nuclear pSTAT5 in FLT3-ITD-positive MOLM-13 cells. Published data demonstrate that nuclear accumulation of pSTAT5 in myeloid blasts of bone marrow biopsies from acute myeloid leukemia (AML) patients correlates with the expression of FLT3-ITD. 30 It will be important to know how FLT3-ITD circumvents SFKmediated cytoplasmic retention of activated STAT5A and how this contributes to acute leukemia. It was shown that signaling of FLT3-ITD differs from wild-type FLT3 because the former signals from the endoplasmatic reticulum. Possibly the mislocalization of FLT3-ITD signaling contributes to the resistance to cytoplasmic retention of activated STAT5A by SFK. 31, 32 Kinase-dead mutants of Hck and Src cannot prevent nuclear accumulation of pSTAT5A in the presence of BCR-ABL. As the kinase activity of SFK is essential, we used SFK inhibitors to test the role of SFK for cytoplasmic retention of pSTAT5A in transfected cells and in the BCR-ABL-positive CML cell line K562. For those experiments it had to be considered that the specificity of kinase inhibitors critically depends on their concentration. The tyrosine kinase inhibitor PP1 was originally described as being specific for SFK with IC50s between 5-50 nM depending on the individual SFK. 33, 34 Later, it turned out that PP1 also inhibits BCR-ABL, albeit at considerably higher doses with an IC50 of about 1 mM.
21,35
Indeed, when we treated K652 cells with 0.1 mM PP1, phosphorylation of Src was not detectable anymore while phosphorylation of BCR-ABL was unaffected. Under these conditions tyrosine phosphorylation of STAT5 was slightly diminished indicating that the kinase activity of SFK contributes to STAT5 activation in BCR-ABL-positive cells as has been reported. 36 However, when SFK are inhibited, the fraction of STAT5A activated through BCR-ABL accumulates in the nucleus as is visible in HEK293T cells transfected with Hck, BCR-ABL and STAT5A as well as for the endogenous STAT5A in K562 cells. These findings argue for an essential function of SFK in the cytoplasmic retention of pSTAT5A in BCR-ABL-positive cells.
Latent, non-phosphorylated STAT5A is distributed equally between the cytoplasm and the nucleus. We observed that overexpression of SFK not only prevented nuclear accumulation but redistributed STAT5A to the cytoplasm. Furthermore, in the majority of the confocal images a colocalization of SFK and STAT5A is visible. Thus, a stable interaction of STAT5A with membrane-bound SFK might cause redistribution to the cytoplasmic compartment. This idea is supported by the coprecipitation of Src with STAT5A and the membrane recruitment of STAT5A tagged with a strong NLS. The interaction depends on an intact SH2 domain of STAT5A but does not require the SH2 and SH3 domains of Src. Therefore, we conclude that STAT5A stably interacts with a phosphotyrosine motif of Src (Figure 7) . The reported colocalization of STAT5 with Hck in podosomes may also be mediated by this type of interaction.
14 STAT3, another known substrate of Src, cannot coprecipitate Src because the interaction of kinase and substrate is transient, as is typical for a kinasesubstrate interaction. It is tempting to speculate that the unusually stable interaction of Src with its substrate STAT5A has a regulatory function and also affects the binding of other substrates to the Src kinase.
We found that the release from cytoplasmic retention of STAT5A through inhibition of SFK led to enhanced expression of STAT5 target genes, such as the feedback inhibitor cis and the prosurvival protein pim1. 37, 38 The increased nuclear concentration of activated STAT5A is the most obvious explanation for this phenomenon. Another important question is whether the unusual distribution of activated STAT5A in the presence of SFK drives tumor progression or is protective. High STAT5 activity is clearly linked with transformation of myeloid cells. STAT5 target genes promote proliferation and prevent apoptosis in leukemic cells. 37 Disturbance of STAT5A-mediated gene induction through cytoplasmic retention of the transcription factor would therefore oppose tumor progression and reduce oncogenic stress. On the other hand, a growth-promoting role for cytoplasmic STAT5A in the context of Gab2/PI3K/Akt signaling has been proposed and the role of Gab2 emphasized. 10, 27, 39 We could demonstrate that the redistribution of STAT5A is accompanied by a decreased 46, 47 nuclear accumulation of pSTAT5A is prevented resulting in reduced induction of STAT5 target genes. A stable interaction of STAT5A through its SH2 domain with SFK contributes to cytoplasmic retention. The STAT5A/SFK complex might be part of an extended scaffold complex including Gab2, PI3K and Akt. 48 Right scheme: after SFK inhibition STAT5A is released from SFK resulting in nuclear accumulation of phosphorylated STAT5 dimers, which leads to an increased induction of STAT5 target genes. phosphorylation of Akt. We observed an increase of clonal growth of K562 cells after SFK inhibition. This suggests that nuclear accumulation of STAT5 is associated with enhanced tumorigenic properties of colony-forming cells and indicates that the reduced phosphorylation of Akt is outbalanced by the increased induction of prosurvival genes, such as pim1, by nuclear STAT5. 40, 41 In this context, it is of interest that in murine models of leukemia, SFK are required for the induction of B-ALL but not CML. 19 Furthermore, persistently activated STAT5A can trigger senescence as an antiproliferative program of the cell in response to an activated oncogene. 42 This activity depends on the induction of STAT5 target genes and could therefore be diminished by cytoplasmic retention of STAT5A. Clarification of these issues is of considerable importance in light of the fact that second generation Src/Abl inhibitors are regarded as promising drugs in the treatment of CML, other BCR-ABL-positive hematological diseases and other malignancies. 43 Thus, the impact of SFK on STAT5 signaling needs further attention.
MATERIALS AND METHODS

Cytokines and antibodies
Oncostatin M (Peprotech, London, UK) was used at a concentration of 5 ng/ml. Anti-pY All media were supplemented with 10% fetal calf serum and 25 U/ml penicillin/streptomycin (Lonza, Verviers, Belgium). Cells were incubated at 37 1C in a water-saturated atmosphere with 5% CO 2 . PP1 was purchased from Sigma.
Purification of hematopoietic progenitor cells from patient blood
Peripheral blood from a patient diagnosed in the untreated chronic phase of CML was obtained upon written informed consent. After Ficoll gradient centrifugation CD34 þ cells were purified using a Midi-MACS CD34 isolation kit (Miltenyi Biotec, Bergisch-Gladbach, Germany), as previously described. 44 Purity of CD34 þ cells as determined by flow cytometry was above 95%.
Preparation of cell lysates, SDS-PAGE and immunoblotting
Cells were lysed, proteins separated by SDS-PAGE and transferred to a polyvinylidene fluoride membrane (PALL, Dreieich, Germany) according to standard procedures. 45 The membrane was blocked with 10% Bovine serum albumin in TBS-N buffer and incubated with the primary antibody for 12 h. The membrane was washed twice with TBS-N for 15 min and treated with a suitable secondary antibody conjugated to horseradish peroxidase for 1 h. Bound antibodies were detected by chemiluminescence (ECL, Millipore, Billerica, MA, USA).
Immunoprecipitation
Transfected HEK293T cells from a 10-cm dish were lysed for 30 min in Frackelton buffer (10 mM Tris-HCL, pH 7.1, 30 mM Na 4 P 2 O 7 , 50 mM NaCl, 50 mM NaF, 1% Triton X-100). Lysates were cleared by centrifugation. Protein A Sepharose CL-4B (GE Healthcare, Dornstadt, Germany) was incubated for 5 h with 2 ml anti-GFP antibody and subsequently mixed with the lysates. After 12 h the immune complexes were washed three times with phosphate-buffered saline and Laemmli buffer was added, followed by SDS-PAGE and immunoblotting.
Indirect immunofluorescence and confocal microscopy
Primary CML cells were prepared using a cytospin. Other cells were grown on polylysine-coated glass cover slips. Fixation of cells and immunostaining has been described previously. 45 Primary antibodies were diluted 1:100, secondary Cy2-, Cy3-(Jackson ImmunoResearch Laboratories, West Grove, PA, USA) or Alexa Fluor-488-(Invitrogen) conjugated antibodies 1:200 or 1:1000 and applied for 45 min. DRAQ5 (Biostatus, Leicestershire, UK) was added to the secondary antibody. The cover slips were mounted with ImmuMount (Thermo Scientific, Pittsburgh, PA, USA). Fluorescence and DIC images were generated with a Zeiss LSM 710 confocal microscope (Zeiss, Jena, Germany). Adherent cells were examined with a Zeiss LD C-apochromat 40 Â /1.1 water objective, K562, MOLM-13 and primary CML cells with a Zeiss plan-apochromat 63 Â /1.4 DIC oil objective. Confocal images represent confocal slices of B1 mm. Intensity profiles were generated with the ZEN 2009 software (Zeiss).
Quantitative RT-PCR K562 cells were plated at a density of 2.5 Â 10 5 cells/ml and cultured for 24 h. PP1 (0.1 mM) was added for 1 h. RNA was prepared with the RNeasy Kit (Qiagen, Hilden, Germany). The Omniscript-RT-PCR-Kit (Qiagen) was used for synthesis of cDNA. Real-time RT-PCR was performed using the TaqMan system (Applied Biosystems, Foster City, CA, USA) in a Rotor-Gene Q thermocycler (Qiagen). TaqMan probes for cis (Hs01003603_m1), pim1 (Hs01065498_m1) and as an internal standard hprt1 (Hs99999909_m1, Applied Biosystems) were used.
Colony formation assay K562 cells were mixed with methylcellulose (MethoCult H4100, Stem Cell Technologies, Grenoble, France) in a density of 500 cells/ml. The methylcellulose was supplemented with 0.1 mM PP1 or 0.5 mM imatinib. Untreated samples served as reference. The methylcellulose/cell suspension was plated in six-well plates using blunt-end needles (16G, 1 ml/well). Assays were performed in duplicates. The colonies were counted under a light microscope.
